Liver grafts from anti-hepatitis B core positive donors: A systematic review

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 272-279

  Cholongitas, Evangelos ^a   Papatheodoridis, George V ^b   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anti HBc positive donors; De novo HBV infection; Hepatitis B immunoglobulin; Lamivudine; Liver transplantation; Marginal donors; Vaccination

Indexed keywords

ADEFOVIR; CYCLOSPORIN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; STEROID; TACROLIMUS; TENOFOVIR; VIRUS DNA;

DRUG EFFICACY; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER GRAFT; LIVER TRANSPLANTATION; ORGAN DONOR; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPHYLAXIS; REVIEW; SAFETY; SURVIVAL RATE; SYSTEMATIC REVIEW;

ALGORITHMS; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 75349089062     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.009     Document Type: Review

References (55)

1. Nadig S.N., Bratton C.F., and Karp S.J. Marginal donors in liver transplantation: expanding the donor pool. J Surg Educ 64 (2007) 46-50
2. Marusawa H., Uemoto S., Hijikata M., Ueda Y., Tanaka K., Shimotohno K., et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31 (2000) 488
3. Mason A., Xu L., Guo L., Kuhns M., and Perrillo R. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27 (1998) 1736-1742
4. Scullard G., Smith C., Merigan T., Robinson W., and Gregory P. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81 (1981) 987-991
5. Rokuhara A., Tanaka E., Yagi S., Mizokami M., Hasshikura Y., Kawasaki S., et al. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 62 (2000) 471-478
6. Jilg W., Sieger E., Zachoval R., and Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 23 (1995) 14-20
7. Burton J., and Shaw-Stiffel T. Use of hepatitis B core antibody positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 9 (2003) 837-842
8. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 15 (2009) 223-232
9. Dickson R.C., Everhart J.E., Lake J.R., Wei Y., Seaberg E.C., Wiesner R.H., et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 113 (1997) 1668-1674
10. Prieto M., Gomez M.D., Berenguer M., Cordoba J., Rayon J.M., Pastor M., et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 7 (2001) 51-58
11. Manzarbeitia C., Reich D.J., Ortiz J.A., Rothstein K.D., Araya V.R., and Munoz S.J. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 8 (2002) 556-561
12. Douglas D., Rakela J., Wright T., Krom R.A., and Wiesner R.H. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 3 (1997) 105-111
13. Shinji U., Kohachiro S., Hiroyuki M., Yukihiro I., Katsuhiro A., Hiroto E., et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65 (1998) 494-499
14. Lee K., Wai C., Lim S., Manjit K., Lee H.L., Da Costa M., et al. Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 7 (2001) 469
15. Lo C., Fan S., Liu C., Yong B.H., Wong Y., Ng I.O., et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 9 (2003) 827-832
16. Chen Y.S., Wang C.C., deVilla V.H., Wang S.H., Cheng Y.F., Huang T.L., et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transpl 16 (2002) 405-409
17. McQuillan G., Coleman P., Kruszon-Moran D., Moyer L., Lambert S., and Margolis H. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Survey, 1976 through 1994. Am J Public Health 89 (1999) 14-18
18. Fontana R.J., and Merion R.M. Are we ready for marginal hepatitis B core antibody-positive living liver donors?. Liver Transpl 9 (2003) 833-836
19. Yu A.S., Vierling J.M., Colquhoun S.D., Arnaout W.S., Chan C.K., Khanafshar E., et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 7 (2001) 513-517
20. Joya-Vazquez F.S., Dodson F.S., Dvorchik I., Gray E., Chesky A., Demetris A.J., et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 73 (2002) 1598-1602
21. Roque-Afonso A.M., Feray C., Samuel D., Simoneau D., Roche B., Emile J.F., et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50 (2002) 95-99
22. Nery J.R., Nery-Avila C., Reddy K.R., Cirocco R., Weppler D., Levi D.M., et al. Use of liver grafts from donors positive for anti-hepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 75 (2003) 1179-1186
23. Montalti R., Nardo B., Bertelli R., Beltempo P., Puviani L., Vivarelli M., et al. Donor pool expansion in liver transplantation. Transplant Proc 36 (2002) 520-522
24. Donataccio D., Roggen F., De Reyck C., Verbaandert C., Bodeus M., and Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 19 (2006) 38-44
25. Prakoso E., Strasser S.I., Koorey D.J., Verran D., and McCaughan G.W. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transpl 20 (2006) 369-373
26. Celebi Kodak A., Karasu Z., Kilic M., Ozacar T., Tekin F., Gunsar F., et al. Living donor liver transplantation from hepatitis B core antibody positive donors. Transplant Proc 39 (2007) 1488-1490
27. De Feo T., Poli F., Mozzi F., Moretti M.P., Scalamogna M., and Collaborative Kidney Liver and Heart North Italy Transplant Program Study Groups. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 37 (2005) 1238-1239
28. Suehiro T., Shimada M., Kishikawa K., Shimura T., Soejima Y., Yoshizumi T., et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 25 (2005) 1169-1174
29. Dodson S.F., Issa S., Araya V., Gayowski T., Pinna A., Eghtesad B., et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 64 (1997) 1582-1584
30. Crespo J., Fabrega E., Casafont F., Rivero M., Heras G., de la Pepa J., et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 5 (1999) 175-183
31. Holt C.D., Thomas R., van Thiel D.H., and Brems J.J. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 137 (2002) 572-575
32. Loss Jr. G., Mason A., Nair S., Blazek J., Farr G., Guo L., et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?. Liver Transpl 12 (2003) 1258-1264
33. Takemura N., Sugawara Y., Tamura S., and Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci 52 (2007) 2472-2477
34. Fabrega E., Garcia-Suarez C., Guerra A., Orive A., Casafont F., Crespo J., et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 9 (2003) 916-920
35. Dodson F., Bonham C., Geller D., Cacciarelli T.V., Rakela J., and Fung J.J. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68 (1999) 1058-1061
36. Barcena R., Moraleda G., Moreno J., Dolore Martin M., de Vicente E., Nupo J., et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 12 (2006) 2070-2074
37. Barcena Marugan R., Garcia-Hoz F., Vazquez Romero M., Nash R., Mateos M., Gonzalez Alonso R., et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 97 (2002) 2398-2401
38. Villamil I., Gonzalez-Quintela A., Aquilera A., Tome S., Otero E., Castroagudin F.J., et al. Truly de novo HBV infection after liver transplantation. Am J Gastroenterol (2004) 767-768
39. Castells L., Vargas V., Rodrygez F., Allende H., Jardy R., Margarit C., et al. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplant Proc 31 (1999) 2464-2465
40. Nery J.R., Gedaly R., Vianna R., Berho M., Weppler D., Levi D.M., et al. Are liver grafts from hepatitis B surface antigen negative/anti-hepatitis B core antibody positive donors suitable for transplantation?. Transplant Proc 33 (2001) 1521-1522
41. Chazouilleres O., Mamish D., Kim M., Carey K., Ferrell L., Roberts J., et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 343 (1994) 142-146
42. Wachs M.E., Amend W.J., Ascher N.L., Bretan P.N., Emond J., Lake J.R., et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 59 (1995) 230-234
43. Jain A., Orloff M., Abt P., Kashyap R., Mohanka R., Lansing K., et al. Use of hepatitis B core antibody positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 37 (2005) 3187-3189
44. Lin C.C., Chen C.L., Concejero A., Wang C.C., Wang S.H., Liu Y.W., et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 7 (2007) 195-200
45. Kwon C., Suh K., Yi N., Chang S., Cho Y., Lee H., et al. Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant 10 (2006) 479-486
46. Hwang S., Moon D.B., Lee S.G., Park K.M., Kim K.H., Ahn C.S., et al. Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantation. Transplantation 75 (2003) S45-S48
47. Umeda M., Marusawa H., Ueda M., Takada Y., Egawa H., Uemoto S., et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 6 (2006) 2680-2685
48. Soejima Y., Ikegami T., Taketomi A., Yoshizumi T., Uchiyama H., Harada N., et al. Hepatitis B vaccination after living donor liver transplantation. Liver Int 27 (2007) 977-982
49. Park J.B., Kwon C.H., Lee K.W., Choi G.S., Kim D.J., Seo J.M., et al. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int 21 (2008) 346-352
50. Lee K., Lee D., and Lee H. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 36 (2004) 2311-2312
51. Papatheodoridis G.V., Sevastianos V., and Burroughs A.K. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 3 (2003) 250-258
52. Segovia R., Sanchez-Fueyo A., Rimola A., Grande L., Bruguera M., Costa J., et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 7 (2001) 106-112
53. Gish R.G., and McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 12 (2006) S54-S64
54. Sung J. Hepatitis B virus infection and its sequelae in Taiwan. Gastroenterol Jpn 19 (1984) 363-366
55. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195